Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

Prior to the advent of VEGF-targeted therapies, renal cell carcinoma (RCC) was among the few solid tumors shown to respond to cytokine-based therapies such as interleukin-2 (IL-2) and interferon alpha. Previous work has shown that aminobisphosphonates, including zoledronic acid (ZA), are capable of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lang, Joshua M., Kaikobad, Mahazarin R., Wallace, Marianne, Staab, Mary Jane, Horvath, Dorothea L., Wilding, George, Liu, Glenn, Eickhoff, Jens C., McNeel, Douglas G., Malkovsky, Miroslav
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3177972/
https://ncbi.nlm.nih.gov/pubmed/21647691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-011-1049-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados